| Treatment | Total costs | Total QALYs | ICER |
|---|---|---|---|
| FEV1% utility | |||
| Placebo | £92,040 | 12.91 | - |
| Nebulised colistimethate sodium | £105,872 | 13.06 | £93,317 |
| Nebulised tobramycin | £244,919 | 13.10 | £2,987,483 |
| Tobramycin dry powder | £274,658 | 12.99 | Dominated |
| Tinnitus excluded | |||
| Placebo | £92,040 | 11.25 | - |
| Nebulised colistimethate sodium | £105,872 | 11.52 | £52,168 |
| Nebulised tobramycin | £205,702 | 11.53 | £6,981,278 |
| Tobramycin dry powder | £254,328 | 11.39 | Dominated |
| Exacerbation cost | |||
| Placebo | £19,008 | 11.25 | - |
| Nebulised colistimethate sodium | £37,435 | 11.52 | £69,499 |
| Nebulised tobramycin | £177,274 | 11.57 | £2,840,324 |
| Tobramycin dry powder | £201,894 | 11.43 | Dominated |
| Number of exacerbations | |||
| Placebo | £180,963 | 10.02 | - |
| Nebulised colistimethate sodium | £189,200 | 10.37 | £24,043 |
| Nebulised tobramycin | £327,283 | 10.43 | £2,206,522 |
| Tobramycin dry powder | £363,255 | 10.20 | Dominated |
| Konstan 2011 FEV1% effect for tobramycin dry powder | |||
| Placebo | £92,040 | 11.25 | - |
| Nebulised colistimethate sodium | £105,872 | 11.52 | £52,168 |
| Nebulised tobramycin | £244,919 | 11.57 | £2,824,240a |
| Tobramycin dry powder | £274,077 | 11.65 | £355,982b |
| Lenoir 2007 FEV1% effect for nebulised tobramycin | |||
| Placebo | £92,040 | 11.25 | - |
| Nebulised colistimethate sodium | £105,872 | 11.52 | £52,168 |
| Nebulised tobramycin | £244,494 | 11.74 | £622,576 |
| Tobramycin dry powder | £274,658 | 11.43 | Dominated |
| Within-trial analysis | |||
| Placebo | £3,171 | 0.42 | - |
| Nebulised colistimethate sodium | £4,421 | 0.42 | Dominated |
| Nebulised tobramycin | £8,417 | 0.42 | £1,524,290 |
| Tobramycin dry powder | £9,641 | 0.43 | £179,805 |
| Nebulised colistimethate sodium cost | |||
| Placebo | £92,040 | 11.25 | - |
| Nebulised colistimethate sodium | £146,602 | 11.52 | £205,775 |
| Nebulised tobramycin | £244,919 | 11.57 | £1,996,961 |
| Tobramycin dry powder | £274,658 | 11.43 | Dominated |
| Nebulised tobramycin drug cost | |||
| Placebo | £92,040 | 11.25 | - |
| Nebulised colistimethate sodium | £105,872 | 11.52 | £52,168 |
| Nebulised tobramycin | £251,445 | 11.57 | £2,956,786 |
| Tobramycin dry powder | £274,658 | 11.43 | Dominated |
| Nebulised colistimethate sodium dose | |||
| Placebo | £92,040 | 11.25 | - |
| Nebulised colistimethate sodium | £123,783 | 11.52 | £119,716 |
| Nebulised tobramycin | £244,919 | 11.57 | £2,460,447 |
| Tobramycin dry powder | £274,658 | 11.43 | Dominated |
| WinBUGS | |||
| Placebo | £92,171 | 11.25 | - |
| Nebulised colistimethate sodium | £106,293 | 11.51 | £54,079 |
| Nebulised tobramycin | £245,335 | 11.56 | £2,820,226 |
| Tobramycin dry powder | £275,109 | 11.42 | Dominated |
| PAS | |||
| Placebo | No change | 11.25 | - |
| Nebulised colistimethate sodium | No change | 11.52 | No change |
| Nebulised tobramycin | Reduced | 11.57 | Reduced (>£30,000) |
| Tobramycin dry powder | Reduced | 11.43 | Dominated |
FEV, forced expiratory volume; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; PAS, patient access scheme; SA, sensitivity analysis
Extended dominance
ICER £1,293,885 when nebulised tobramycin excluded
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.